Contrasting Sol-Gel Technologies (SLGL) & Its Rivals

Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Sol-Gel Technologies to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.

Earnings & Valuation

This table compares Sol-Gel Technologies and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sol-Gel Technologies $19.39 million -$6.13 million -10.51
Sol-Gel Technologies Competitors $3.55 billion $3.17 billion 559.01

Sol-Gel Technologies’ competitors have higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Sol-Gel Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies’ competitors have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Sol-Gel Technologies and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sol-Gel Technologies 1 0 4 2 3.00
Sol-Gel Technologies Competitors 7845 13798 25820 1039 2.41

Sol-Gel Technologies presently has a consensus target price of $197.50, suggesting a potential upside of 259.35%. As a group, “Pharmaceuticals” companies have a potential upside of 24.06%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Sol-Gel Technologies is more favorable than its competitors.

Institutional & Insider Ownership

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Sol-Gel Technologies and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sol-Gel Technologies -1,115.39% -39.28% -33.79%
Sol-Gel Technologies Competitors -2,400.61% -215.91% -15.58%

Summary

Sol-Gel Technologies beats its competitors on 8 of the 13 factors compared.

Sol-Gel Technologies Company Profile

(Get Free Report)

Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.